Home / Pharmaceutical company intelligence
Pacific Pharmaceutical Ltd logo
Pharmaceutical company intelligence

Pacific Pharmaceutical Ltd

Pharmaceutical manufacturer · Lahore · Pakistan

Lahore pharmaceutical manufacturer established in 1991 with domestic and international operations and MHRA/EU-GMP certified manufacturing capabilities.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date1 Jul 2024Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Pacific Pharmaceuticals Ltd.
Company type
Pharmaceutical manufacturer
Address
30th KM Multan Road, Lahore, Pakistan
Phone
+92 42 35975291-93
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000902 Pacific Pharmaceuticals Ltd. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000295 45 linked products · source seen 23 Sep 2026 View source ↗
DML 000902 13 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx60public portfolio records represented
REG54unique registrations represented
IDX29indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR48current validated price records
G33generic molecules in indexed catalogue
DF8dosage-form groups
TA10therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage80%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage84%
priced packs safely normalized per unit
Comparable-market coverage79%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixPacific Pharmaceutical LtdShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pacific-pharmaceutical-ltdGenerated 23 Sep 2026Anti-infectives29 · 50%Fluids & supportive care8 · 14%Pain & musculoskeletal7 · 12%Endocrine & metabolic4 · 7%Hematology & thrombosis3 · 5%Reproductive & genitourinary2 · 3%Cardiovascular2 · 3%Other therapeutic areas3 · 5%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioPacific Pharmaceutical LtdDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pacific-pharmaceutical-ltdGenerated 23 Sep 202658presentationsTablet37 · 64%Infusion6 · 10%Capsule5 · 9%Injection4 · 7%Suspension3 · 5%Cream1 · 2%Other forms2 · 3%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionPacific Pharmaceutical LtdCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pacific-pharmaceutical-ltdGenerated 23 Sep 202646comparable productsBelow peer median21 · 46%Near peer median10 · 22%Above peer median15 · 33%Company median price position-2.2%Lowest-price equivalents12Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsPacific Pharmaceutical LtdCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pacific-pharmaceutical-ltdGenerated 23 Sep 2026M/s. Genix Pharma (Pvt) Ltd.18 shared55% overlapPharmasol (Pvt) Ltd.17 shared52% overlapZafa Pharmaceutical Laboratories (P…17 shared52% overlapNeutro Pharma (Pvt.) Ltd.,17 shared52% overlapGlobal Pharmaceuticals (Pvt.) Ltd.16 shared48% overlapShaigan Pharmaceuticals (Pvt) Ltd16 shared48% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives29 products · 50%
Fluids & supportive care8 products · 14%
Pain & musculoskeletal7 products · 12%
Endocrine & metabolic4 products · 7%
Hematology & thrombosis3 products · 5%
Reproductive & genitourinary2 products · 3%
Cardiovascular2 products · 3%
Gastrointestinal & hepatology1 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antimycobacterials15 products · 26%
Fluids, electrolytes & diluents8 products · 14%
Analgesics / NSAIDs6 products · 10%
Antimalarials4 products · 7%
Antidiabetic medicines4 products · 7%
Fluoroquinolone antibacterials3 products · 5%
Anticoagulants2 products · 3%
Penicillin antibacterials2 products · 3%
Formulation footprint

Dosage forms

Tablet37 products
Infusion6 products
Capsule5 products
Injection4 products
Suspension3 products
Cream1 products
Drops1 products
Syrup1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 RIFADINRifampicin 5presentations 150 mg, 2% w/v, 300 mg, 450 mg · Capsule, Suspension, Tablet #2 Pacific WFIWater for Injection 4presentations 10 mL presentation, 5 mL · Injection #3 RIFINAHRifampicin + Isoniazid 4presentations 100 mg + 50 mg, 150 mg + 75 mg, 300 mg + 150 mg, 450 mg + 300 mg · Syrup, Tablet #4 XibenIbuprofen 3presentations 100 mg/5 mL, 400 mg/100 mL · Suspension, Infusion #5 CINQUIN CINQUINLevofloxacin 2presentations 250 mg, 500 mg · Tablet #6 GlifozinEmpagliflozin 2presentations 10 mg, 25 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2146% of comparable products
Near market median10within ±5% of median
Above market median1533% of comparable products
Lowest-price equivalents12ties included
Company median price position -2.2% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
CINQUIN CINQUIN 500 mgLevofloxacin · Tablet · 10’s PKR 36.20/tablet-54.2% vs market median CINQUIN CINQUIN 250 mgLevofloxacin · Tablet · 10’s PKR 23.16/tablet-52.0% vs market median Ximthro Ximthro 250 mgAzithromycin · Tablet · 6's PKR 26.75/tablet-43.2% vs market median Ximthro Ximthro 500 mgAzithromycin · Tablet · 6's PKR 49.04/tablet-42.3% vs market median Eltam Eltam 75 mgOseltamivir · Capsule · 10’s PKR 80.25/capsule-33.4% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 18shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 17shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 17shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 17shared generics Global Pharmaceuticals (Pvt.) Ltd.224 products · 80 generics 16shared generics Shaigan Pharmaceuticals (Pvt) Ltd198 products · 74 generics 16shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers53Distinct registrations among indexed, published, presentation-validated products only
Verified price observations58
Products with a verified price58
Products with multiple price observations0
Source records with multiple versions58
Latest portfolio source check22 Sep 2026
Latest effective price date1 Jul 2024
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

54 unique registration(s) · 29 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
CINQUIN CINQUIN Levofloxacin 250 mg Tablet 10’s 029290 PKR 231.55 PKR 23.16/tablet 52% below median
CINQUIN CINQUIN Levofloxacin 500 mg Tablet 10’s 029291 PKR 362.04 PKR 36.20/tablet 54% below median
Eltam Eltam Oseltamivir 75 mg Capsule 10’s 106081 PKR 802.50 PKR 80.25/capsule 33% below median
Etham Etham Ethambutol 400 mg Tablet 100's 057252 PKR 1,671.34 PKR 16.71/tablet Near median
FANTAR DS Artemether + Lumefantrine 40 mg + 240 mg Tablet 8’s 076802 PKR 527.40 PKR 65.93/tablet Near median
FLAMIL FLAMIL Silver sulfadiazine 1 % Cream 50g 067972 PKR 190.81 PKR 3.82/g 8% above median
Maquin Chloroquine 250 mg Tablet 500's 106082 PKR 1,503.33 PKR 3.01/tablet 95% above median
Maquin-H Hydroxychloroquine 200 mg Tablet 50's 106083 PKR 481.50 PKR 9.63/tablet 33% below median
Maquin-H Hydroxychloroquine 200 mg Tablet 30's 106083 PKR 288.90 PKR 9.63/tablet 33% below median
Meitreo Metronidazole 500 mg/100 mL IV infusion 100 ml (Plastic Bottle) 109577 PKR 175.48 — No comparator
RIFADIN Rifampicin 150 mg Capsule 48’s 001855 PKR 175.38 PKR 3.65/capsule 24% below median
RIFADIN Rifampicin 2% w/v Suspension 60ml 002656 PKR 108.08 PKR 1.80/mL No comparator
RIFADIN Rifampicin 450 mg Tablet 24’s 004631 PKR 372.25 PKR 15.51/tablet 21% below median
RIFADIN Rifampicin 300 mg Capsule 48’s 004693 PKR 569.79 PKR 11.87/capsule Near median
RIFADIN Rifampicin 600 mg Tablet 8’s 005847 PKR 230.53 PKR 28.82/tablet Near median
RIFATER Rifampicin + Isoniazid + Pyrazinamide 120 mg + 50 mg + 300 mg Tablet 60’s 009510 PKR 605.10 PKR 10.09/tablet No comparator
RIFIN FORTE Rifampicin + Isoniazid + Pyrazinamide + Ethambutol 150 mg + 75 mg + 400 mg + 275 mg Tablet 80’s 024030 PKR 3,016.54 PKR 37.71/tablet 11% above median
RIFIN-E Rifampicin + Isoniazid + Ethambutol 150 mg + 75 mg + 275 mg Tablet 80’s 043696 PKR 1,220.09 PKR 15.25/tablet 146% above median
RIFIN-P Rifampicin + Isoniazid + Pyrazinamide 150 mg + 75 mg + 400 mg Tablet 60’s 022893 PKR 582.51 PKR 9.71/tablet 13% below median
RIFIN-P PEDIATRIC Rifampicin + Isoniazid + Pyrazinamide 60 mg + 30 mg + 150 mg Tablet 100’s 069167 PKR 1,368.53 PKR 13.69/tablet 64% above median
RIFINAH Rifampicin + Isoniazid 300 mg + 150 mg Tablet 32’s 005559 PKR 1,280.92 PKR 40.03/tablet 146% above median
RIFINAH Rifampicin + Isoniazid 450 mg + 300 mg Tablet 32’s 012102 PKR 1,894.16 PKR 59.19/tablet 8% below median
RIFINAH Rifampicin + Isoniazid 100 mg + 50 mg Syrup 50ml 057253 PKR 151.53 PKR 3.03/mL No comparator
RIFINAH Rifampicin + Isoniazid 150 mg + 75 mg Tablet 48’s 075566 PKR 461.73 PKR 9.62/tablet Near median
TAMOXIDEX Tamoxifen 20 mg Tablet 30's 098134 PKR 655.73 PKR 21.86/tablet 22% below median
TAMOXIDEX TAMOXIDEX Tamoxifen 10 mg Tablet 10's 098133 PKR 148.36 PKR 14.84/tablet 16% below median
VELOXIN Moxifloxacin 400 mg Tablet 5’s 046000 PKR 641.27 PKR 128.25/tablet 30% below median
Ximthro Ximthro Azithromycin 500 mg Tablet 6's 106084 PKR 294.25 PKR 49.04/tablet 42% below median
Ximthro Ximthro Azithromycin 250 mg Tablet 6's 106085 PKR 160.50 PKR 26.75/tablet 43% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Pacific Pharmaceutical Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/pacific-pharmaceutical-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.